BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 26021554)

  • 1. Impact of neoadjuvant therapy on cancer-associated fibroblasts in rectal cancer.
    Verset L; Tommelein J; Moles Lopez X; Decaestecker C; Boterberg T; De Vlieghere E; Salmon I; Mareel M; Bracke M; De Wever O; Demetter P
    Radiother Oncol; 2015 Sep; 116(3):449-54. PubMed ID: 26021554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic implications of the lymph node count after neoadjuvant treatment for rectal cancer.
    Persiani R; Biondi A; Gambacorta MA; Bertucci Zoccali M; Vecchio FM; Tufo A; Coco C; Valentini V; Doglietto GB; D'Ugo D
    Br J Surg; 2014 Jan; 101(2):133-42. PubMed ID: 24375303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histological grading based on poorly differentiated clusters is predictive of tumour response and clinical outcome in rectal carcinoma treated with neoadjuvant chemoradiotherapy.
    Reggiani Bonetti L; Lionti S; Domati F; Pagliani G; Mattioli E; Barresi V
    Histopathology; 2017 Sep; 71(3):393-405. PubMed ID: 28425130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of adjuvant chemotherapy on survival and recurrence after curative rectal cancer surgery in patients who are histologically node negative after neoadjuvant chemoradiotherapy.
    Baird DLH; Denost Q; Simillis C; Pellino G; Rasheed S; Kontovounisios C; Tekkis PP; Rullier E
    Colorectal Dis; 2017 Nov; 19(11):980-986. PubMed ID: 28493401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of progression-free survival for locally advanced rectal cancer by MRI after neoadjuvant chemoradiotherapy and total mesorectal excision].
    Zhang JX; Yang Z; Fan P; Zhang JJ; Xin L; Hou LN; Du XS; Yang XT
    Zhonghua Zhong Liu Za Zhi; 2018 Feb; 40(2):121-126. PubMed ID: 29502372
    [No Abstract]   [Full Text] [Related]  

  • 6. Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation.
    Lin CY; Tian YF; Wu LC; Chen LT; Lin LC; Hsing CH; Lee SW; Sheu MJ; Lee HH; Wang YH; Shiue YL; Wu WR; Huang HY; Hsu HP; Li CF; Chen SH
    J Clin Pathol; 2012 Aug; 65(8):687-92. PubMed ID: 22569540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of DSG3 in rectal adenocarcinoma treated with preoperative chemoradiotherapy.
    Chao TB; Li CF; Lin CY; Tian YF; Chang IW; Sheu MJ; Lee YE; Chan TC; He HL
    Future Oncol; 2016 Jun; 12(12):1457-67. PubMed ID: 27040321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast growth factor receptor 2 overexpression is predictive of poor prognosis in rectal cancer patients receiving neoadjuvant chemoradiotherapy.
    Li CF; He HL; Wang JY; Huang HY; Wu TF; Hsing CH; Lee SW; Lee HH; Fang JL; Huang WT; Chen SH
    J Clin Pathol; 2014 Dec; 67(12):1056-61. PubMed ID: 25271212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NF-κB/p65 expression before and after treatment in rectal cancer patients undergoing neoadjuvant (chemo)radiotherapy and surgery: prognostic marker for disease progression and survival.
    Voboril R; Rychterova V; Voborilova J; Kubecova M; Fanta J; Dvorak J
    Neoplasma; 2016; 63(3):462-70. PubMed ID: 26952512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic impact of preoperative blood monocyte count in pathological T3N0M0 rectal cancer without neoadjuvant chemoradiotherapy.
    Zhang LN; Xiao W; OuYang PY; You K; Zeng ZF; Ding PR; Pan ZZ; Xu RH; Gao YH
    Tumour Biol; 2015 Sep; 36(10):8213-9. PubMed ID: 25994571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extramural perineural invasion in pT3 and pT4 rectal adenocarcinoma as prognostic factor after preoperative chemoradiotherapy.
    Lino-Silva LS; Salcedo-Hernández RA; España-Ferrufino A; Ruiz-García EB; Ruiz-Campos M; León-Takahashi AM; Meneses-García A
    Hum Pathol; 2017 Jul; 65():107-112. PubMed ID: 28526604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.
    Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
    Int J Clin Oncol; 2016 Oct; 21(5):946-952. PubMed ID: 26919982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemotherapy after neoadjuvant chemoradiation and curative resection for rectal cancer: is it necessary for all patients?
    Jung KU; Kim HC; Park JO; Park YS; Park HC; Choi DH; Cho YB; Yun SH; Lee WY; Chun HK
    J Surg Oncol; 2015 Mar; 111(4):439-44. PubMed ID: 25488390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival.
    Sprenger T; Conradi LC; Beissbarth T; Ermert H; Homayounfar K; Middel P; Rüschoff J; Wolff HA; Schüler P; Ghadimi BM; Rödel C; Becker H; Rödel F; Liersch T
    Cancer; 2013 Jan; 119(1):26-35. PubMed ID: 22736392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience.
    Tseng MSF; Zheng H; Ng IWS; Leong YH; Leong CN; Yong WP; Cheong WK; Tey JCS
    Singapore Med J; 2018 Jun; 59(6):305-310. PubMed ID: 29167909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High EREG Expression Is Predictive of Better Outcomes in Rectal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy.
    Lin CY; Hsieh PL; Chou CL; Yang CC; Lee SW; Tian YF; Shiue YL; Li WS
    Oncology; 2020; 98(8):549-557. PubMed ID: 32408308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Surgical Complications Following Resection of Locally Advanced Rectal Adenocarcinoma on Adjuvant Chemotherapy Delivery and Survival Outcomes.
    Jamnagerwalla M; Tay R; Steel M; Keck J; Jones I; Faragher I; Gibbs P; Wong R
    Dis Colon Rectum; 2016 Oct; 59(10):916-24. PubMed ID: 27602922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk-Adapted Adjuvant Chemotherapy After Concomitant Fluoropyrimidine-Radiotherapy Neoadjuvant Treatment for Patients With Resectable CT3-4 or N+ Rectal Cancer: Five-Year Disease-Free Survival Results of a Single-Center Series.
    Sastre J; Serrano JJ; Fernández C; Ramirez C; Ortega L; García-Paredes B; Corona J; Alfonso R; Córdoba S; Díaz-Rubio E
    Clin Colorectal Cancer; 2016 Jun; 15(2):128-34. PubMed ID: 26385572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 as a limited predictor of the therapeutic response to neoadjuvant therapy in locally advanced rectal cancer.
    Kwon MJ; Soh JS; Lim SW; Kang HS; Lim H
    Pathol Res Pract; 2019 May; 215(5):910-917. PubMed ID: 30772061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expression and prognostic significance of bcl-2-associated transcription factor 1 in rectal cancer following neoadjuvant therapy.
    Brown GT; Cash B; Alnabulsi A; Samuel LM; Murray GI
    Histopathology; 2016 Mar; 68(4):556-66. PubMed ID: 26183150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.